At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Beraprost Sodium Modified Releasedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients.
In Brief
A Phase 2 clinical trial evaluating Beraprost Sodium Modified Release for Pulmonary Arterial Hypertension. Completed, enrolled 18 participants across 6 sites in 3 countries.
Detailed Summary
This is an open-label extension study for patients who participated in the BPS-MR-PAH-201 study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesBelgium, Ireland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2008
Enrollment StartFeb 2009
Primary CompletionNov 2013
TodayJul 2026
First PostedNov 18, 2008
Enrollment StartFeb 28, 2009
Primary CompletionNov 30, 2013
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 17.6 years ago
Interventions
Beraprost Sodium Modified Releasedrug